Ionis deal delivers for GSK as HBV drug hits the mark in phase 2

Ionis deal delivers for GSK as HBV drug hits the mark in phase 2

Source: 
Pharmaforum
snippet: 

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.